[go: up one dir, main page]

UY27175A1 - Nueva sal succinato de o-desmetil- venlafaxina - Google Patents

Nueva sal succinato de o-desmetil- venlafaxina

Info

Publication number
UY27175A1
UY27175A1 UY27175A UY27175A UY27175A1 UY 27175 A1 UY27175 A1 UY 27175A1 UY 27175 A UY27175 A UY 27175A UY 27175 A UY27175 A UY 27175A UY 27175 A1 UY27175 A1 UY 27175A1
Authority
UY
Uruguay
Prior art keywords
venlafaxina
desmetil
succinate salt
new
new succinate
Prior art date
Application number
UY27175A
Other languages
English (en)
Inventor
Anthony F Adfield
Syed M Shah
Michael W Winkley
Karen W Sutherland
James A Provost
Aeri Park
Rex A Shipplett
Brenton W Russell
Beat T Weber
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26952945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27175(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of UY27175A1 publication Critical patent/UY27175A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se presenta una nueva sal de O-desmetil-venlafaxina, el succinato de O-desmetil-venlafaxina. Asimismo, se presentan composiciones farmacéuticas, formas de dosificación y métodos de utilización
UY27175A 2001-02-12 2002-02-13 Nueva sal succinato de o-desmetil- venlafaxina UY27175A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26821401P 2001-02-12 2001-02-12
US29796301P 2001-06-13 2001-06-13

Publications (1)

Publication Number Publication Date
UY27175A1 true UY27175A1 (es) 2002-09-30

Family

ID=26952945

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27175A UY27175A1 (es) 2001-02-12 2002-02-13 Nueva sal succinato de o-desmetil- venlafaxina

Country Status (31)

Country Link
US (5) US6673838B2 (es)
EP (3) EP1360169B2 (es)
JP (1) JP4220243B2 (es)
KR (1) KR100875610B1 (es)
CN (2) CN100567253C (es)
AR (2) AR032671A1 (es)
AT (1) ATE369330T1 (es)
AU (1) AU2002250058B2 (es)
BR (1) BR0207157A (es)
CA (2) CA2666611A1 (es)
CY (1) CY1106952T1 (es)
DE (1) DE60221642T3 (es)
DK (1) DK1360169T3 (es)
EA (1) EA011451B1 (es)
ES (1) ES2290281T5 (es)
HK (1) HK1057885A1 (es)
HN (1) HN2002000030A (es)
HU (1) HUP0303128A3 (es)
IL (4) IL157340A0 (es)
MX (1) MXPA03007043A (es)
NO (1) NO328807B1 (es)
NZ (1) NZ539791A (es)
PA (1) PA8539901A1 (es)
PE (1) PE20020877A1 (es)
PL (2) PL212943B1 (es)
PT (1) PT1360169E (es)
SI (1) SI1360169T1 (es)
TW (1) TWI318201B (es)
UY (1) UY27175A1 (es)
WO (1) WO2002064543A2 (es)
ZA (1) ZA200307116B (es)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1317012A (zh) 1998-10-30 2001-10-10 味之素株式会社 稳定性优良的天冬甜素衍生物晶体的结晶方法
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
EP1905757A1 (en) * 1999-04-06 2008-04-02 Sepracor Inc. Derivatives of Venlafaxine and methods of preparing and using the same
DK1360169T3 (da) * 2001-02-12 2007-11-26 Wyeth Corp Succinatsalt af O-desmethyl-venlafaxin
US20050244498A1 (en) * 2001-09-14 2005-11-03 Biovail Laboratories, Inc. Modified-release compositions of at least one form of venlafaxine
UA80543C2 (en) * 2001-12-04 2007-10-10 Wyeth Corp Method for the preparation of o-desmethylvenlafaxine
WO2003082261A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Extended release venlafaxine formulations
RU2004139075A (ru) * 2002-06-10 2005-06-27 Уайт (Us) Новые формиат 0-десметилвенлафаксина
CN1678322A (zh) * 2002-08-29 2005-10-05 阿瑞科诺沃治疗有限公司 (4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并[2,3－d]嘧啶的新治疗用途
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
JP2004359665A (ja) * 2003-05-30 2004-12-24 Rohm & Haas Co 生体利用性増強剤を含有する治療組成物
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
KR20060132891A (ko) 2004-02-06 2006-12-22 와이어쓰 다중미립자 ｏ－데스메틸벤라팍신 염 및 그의 용도
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7439280B2 (en) * 2004-04-06 2008-10-21 Basf Corporation Lignocellulosic composite material and method for preparing the same
AU2005266994A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
CN101022794A (zh) * 2004-07-22 2007-08-22 惠氏公司 治疗神经系统障碍和病症的方法
WO2006012476A2 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
US20060193911A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co., Controlled release venlafaxine formulations
CA2601898A1 (en) * 2005-03-31 2006-10-05 Wyeth O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
CN1955159B (zh) * 2005-06-17 2010-11-24 山东绿叶制药有限公司 用于阻断5-羟色胺以及去甲基肾上腺素再摄取的化合物,其制备方法及其用途
MX2008000249A (es) * 2005-07-06 2008-03-18 Sepracor Inc Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
US7687520B2 (en) 2005-07-15 2010-03-30 Wyeth Llc Serotonin and norepinephrine reuptake inhibitors and uses thereof
TW200740724A (en) * 2005-07-15 2007-11-01 Wyeth Corp Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
US7595340B2 (en) 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
GT200600396A (es) * 2005-09-07 2007-04-23 Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales
GT200600397A (es) * 2005-09-07 2007-08-28 Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales
CN1332946C (zh) * 2005-10-21 2007-08-22 中国人民解放军军事医学科学院放射与辐射医学研究所 作用于中枢神经系统的前药
WO2007064697A1 (en) * 2005-12-01 2007-06-07 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
BRPI0619449A2 (pt) * 2005-12-05 2011-03-29 Wyeth Corp processo para a sìntese estereosseletiva de uma (4s ou 4r)-4-benzil-3-[2r ou 2s]-(1-hidroxicicloexil)-(metoxifenil) acetil]-1,3-oxazolidin-2-ona e de um enantiÈmero de uma 2-fenil-2-(1-hidroxicicloalquil) etilamina ou seu sal e compostos
EP1973866A1 (en) 2005-12-20 2008-10-01 Synthon B.V. Process for making desvenlafaxine
MX2007016179A (es) * 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
CA2646368A1 (en) 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Substantially pure o-desmethylvenlafaxine and processes for preparing it
KR101424832B1 (ko) * 2006-05-16 2014-08-06 길리애드 사이언시즈, 인코포레이티드 악성 혈액 종양 치료 방법 및 악성 혈액 종양 치료용 조성물
CA2656166A1 (en) * 2006-07-26 2008-01-31 Teva Pharmaceutical Industries Ltd. Processes for the synthesis of o-desmethylvenlafaxine
CA2656161A1 (en) 2006-07-26 2008-01-31 Teva Pharmaceutical Industries Ltd. Process for the synthesis of o-desmethylvenlafaxine
US20080221356A1 (en) * 2006-07-26 2008-09-11 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20090137846A1 (en) * 2006-07-26 2009-05-28 Valerie Niddam-Hildesheim Processes for the synthesis of O-Desmethylvenlafaxine
US20090069601A1 (en) * 2006-07-26 2009-03-12 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
EP2061750A2 (en) * 2006-08-04 2009-05-27 Medichem, S.A. Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof
CA2659295A1 (en) * 2006-08-08 2008-02-14 Generics [Uk] Limited Novel hydrate form of o-desmethyl venlafaxine succinate
EP2074082A1 (en) * 2006-10-18 2009-07-01 Generics (UK) Limited Polymorphs of o-desmethyl venlafaxine succinate
AR063376A1 (es) * 2006-10-25 2009-01-28 Wyeth Corp Metabolitos aislados de hidroxi y n-oxido y derivados de o-desmetilvenlafaxina y metodos de tratamiento
ATE502028T1 (de) * 2006-12-21 2011-04-15 Pfizer Prod Inc Succinatsalz von 2-((4-(1-methyl-4(pyridin-4-yl)- 1h-pyrazol-3-yl)phenoxy)methyl)chinolin
AR064507A1 (es) * 2006-12-22 2009-04-08 Medichem Sa Nuevas formas solidas cristalinas de forma base de o-desvenlafaxina
US7820716B2 (en) * 2007-01-08 2010-10-26 Mai De Ltd Crystalline polymorphs of desvenlafaxine succinate and their preparations
WO2008090465A2 (en) * 2007-01-22 2008-07-31 Medichem, S.A. Process for synthesizing desvenlafaxine free base and salts or salvates thereof
WO2008093142A1 (en) * 2007-01-31 2008-08-07 Generics [Uk] Limited Process for the preparation of o-desmethyl venlafaxine
NZ579137A (en) * 2007-02-21 2012-05-25 Sunovion Pharmaceuticals Inc Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof
WO2008110338A1 (en) * 2007-03-09 2008-09-18 Synthon B.V. Polymorph of desvenlafaxine succinate
IN2009DN05509A (es) * 2007-03-14 2010-04-30 Teva Pharma
LT2125698T (lt) 2007-03-15 2016-10-10 Auspex Pharmaceuticals, Inc. Deuterintas d9-venlafaksinas
WO2008156748A2 (en) * 2007-06-15 2008-12-24 Teva Pharmaceutical Industries Ltd. Crystal forms of o-desmethylvenlafaxine succinate
US20100210719A1 (en) * 2007-07-12 2010-08-19 Dr. Reddy's Laboratories Ltd. O-desmethylvenlafaxine
WO2009010990A2 (en) * 2007-07-16 2009-01-22 Matrix Laboratories Limited Process for the preparation of o-desmethylvenlafaxine succinate polymorphic forms
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
US20090076162A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched desvenlafaxine
JP2011500605A (ja) * 2007-10-16 2011-01-06 アルファファーム ピーティーワイ リミテッド 制御放出医薬配合物
US20110046231A1 (en) * 2007-10-22 2011-02-24 Actavis Group Ptc Ehf Solid forms of (±)-o-desmethylvenlafaxine salts
US20110118357A1 (en) * 2007-10-26 2011-05-19 Generics Limited Process for preparing o-desmethylvenlafaxine
US8063250B2 (en) 2007-11-26 2011-11-22 Teva Pharmaceutical Industries, Ltd. Crystal forms of O-desmethylvenlafaxine fumarate
EP2085377A1 (en) * 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Novel salts of O-desmethyl-venlafaxine
EP2262758A4 (en) * 2008-03-12 2011-12-07 Reddys Lab Ltd Dr O-desmethylvenlafaxine SALTS
WO2009118758A2 (en) * 2008-03-24 2009-10-01 Sun Pharmaceutical Industries Ltd. Novel crystalline forms of desvenlafaxine succinate
IN2008CH00818A (es) * 2008-04-01 2009-10-09 Actavis Group Ptc Ehf
KR100965527B1 (ko) * 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
EP2119696A1 (en) 2008-05-16 2009-11-18 Krka Preparation of O-desmethylvenlafaxine salts
EP2119695A1 (en) * 2008-05-16 2009-11-18 Krka Preparation of O-desmethylvenlafaxine salts
KR20100132069A (ko) * 2008-06-16 2010-12-16 테바 파마슈티컬 인더스트리즈 리미티드 Ｏ-데스메틸벤라팍신염의 고체 상태
ES2393962T3 (es) * 2008-07-08 2013-01-03 Gilead Sciences, Inc. Sales de compuestos inhibidores del VIH.
US20100016638A1 (en) * 2008-07-21 2010-01-21 Zdenko Hamersak Method for preparation of o-desmethylvenlafaxine using polythiolates
CN102164886A (zh) * 2008-07-30 2011-08-24 基因里克斯(英国)有限公司 用于制备o-去甲文拉法辛的方法
KR101041960B1 (ko) * 2008-08-14 2011-06-16 주식회사 루미맥스테크놀러지 파워 ｌｅｄ를 구비하는 램프 장치
EP2191822A1 (en) * 2008-11-26 2010-06-02 LEK Pharmaceuticals d.d. Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
CZ2008756A3 (cs) * 2008-11-27 2010-03-24 Zentiva, A. S. Zpusob prípravy desvenlafaxinu a jeho solí
ES2343050B1 (es) * 2008-12-16 2011-06-14 Chemo Iberica, S.A. Procedimiento para la preparacion de desvenlafaxina y sus sales de adicion de acido farmaceuticamente aceptables.
CZ301820B6 (cs) * 2009-02-06 2010-06-30 Zentiva, K.S. Nové soli desvenlafaxinu a zpusob jejich prípravy
CZ2009454A3 (cs) 2009-07-15 2010-11-10 Zentiva, K. S. Zpusob prípravy desvenlafaxinu a jeho solí
NZ597550A (en) 2009-07-16 2013-08-30 Cipla Ltd Process for the preparation of o-desmethyl venlafaxine and intermediate for use therein
US20110098506A1 (en) * 2009-10-26 2011-04-28 Intas Pharmaceuticals Limited Method of preparing o-desmethylvenlafaxine
US8754261B2 (en) 2009-12-16 2014-06-17 Pharmathen S.A. Process for the preparation of O-desmethyl-venlafaxine and salts thereof
US20110184067A1 (en) * 2010-01-25 2011-07-28 Intas Pharmaceuticals Ltd. O-desmethylvenlafaxine succinate polymorph & process for preparing thereof
EP2539313A2 (en) * 2010-03-29 2013-01-02 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
WO2011121475A2 (en) 2010-03-31 2011-10-06 Wockhardt Limited Modified release dosage form comprising desvenlafaxine or salts thereof
CZ303249B6 (cs) * 2010-04-06 2012-06-20 Zentiva, K.S. Zpusob výroby 4-(2-(substituovaných)-1-(1-hydroxycyklohexyl)ethyl)fenolu O-demethylací jejich methyletheru pomocí nepáchnoucích aromatických thiolu
CN102212014B (zh) * 2010-04-09 2013-12-25 江苏豪森医药集团有限公司 O-去甲基-文拉法辛的谷氨酸盐的晶型、其制备方法及其在医药上的应用
AU2011251747B2 (en) 2010-05-14 2014-08-07 Alembic Limited Extended release formulations of desvenlafaxine base
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
KR101477155B1 (ko) 2010-10-01 2014-12-29 산동 루예 파마슈티칼 컴파니 리미티드 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도
US8933123B2 (en) 2010-10-08 2015-01-13 Cadila Healthcare Limited Polymorphic forms of O-desmethyl-venlafaxine succinate
WO2012123922A1 (en) 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
PH12013502080A1 (en) 2011-04-12 2017-01-04 Lupin Ltd Modified release pharmaceutical compositions of desvenlafaxine
US8481596B2 (en) 2011-06-08 2013-07-09 Lupin Limited Polymomorph of desvenlafaxine benzoate
UY35091A (es) * 2012-10-24 2014-05-30 Onyx Therapeutics Inc Formulaciones de liberacion modificada para oprozomib
CN104666291A (zh) * 2013-11-26 2015-06-03 山东绿叶制药有限公司 去甲基文拉法辛苯甲酸酯类化合物在制备改善性功能障碍药物中的应用
CN104352469A (zh) * 2014-11-20 2015-02-18 哈尔滨圣吉药业股份有限公司 一种琥珀酸去甲文拉法辛缓释片及其制备方法
CN106146323B (zh) * 2015-04-03 2021-05-25 石药集团中奇制药技术（石家庄）有限公司 一种琥珀酸去甲文拉法辛一水合物新晶型及制备方法
MX367362B (es) 2016-06-29 2019-08-16 Alparis Sa De Cv Nuevas formas solidas de desvenlafaxina.
ES2961706T3 (es) * 2017-02-09 2024-03-13 R L Finechem Private Ltd Un proceso para la preparación de 1-[2-(dimetilamino)-1-(4-hidroxifenil)etil]-ciclohexanol y sales del mismo
CN107082745A (zh) * 2017-04-21 2017-08-22 上海华源医药科技发展有限公司 一种改进的ⅰ型去甲文拉法辛琥珀酸盐的生产方法
EP3655000A4 (en) * 2017-07-11 2021-07-14 Universal Stabilization Technologies, Inc. PROCESS FOR THE PRESERVATION OF BIOPHARMACEUTICALS
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
WO2019031902A2 (ko) 2017-08-11 2019-02-14 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
KR102518632B1 (ko) 2018-04-18 2023-04-06 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
TR201820634A2 (tr) 2018-12-27 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Desvenlafaksi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8902209D0 (en) 1989-02-01 1989-03-22 Wyeth John And Brother Limited Preparation of cyclohexanol derivatives and novel thioamide intermediates
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0647134A4 (en) 1992-06-23 1997-07-30 Sepracor Inc METHODS AND COMPOSITIONS USED TO TREAT DEPRESSION AND OTHER CONDITIONS WITH OPTICALLY PURE SIBUTRAMINE (-).
EP0708639A4 (en) 1992-06-23 1997-08-20 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATMENT OF DEPRESSION AND OTHER DISEASES USING OPTICALLY PURE SIBUTTRAMINE
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
SG47711A1 (en) 1993-06-28 1998-04-17 American Home Prod New treatments using phenehylamine derivatives
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
EP0667150B1 (en) † 1994-02-14 2002-12-11 Wyeth Venlafaxine and its analogues for inducing cognition enhancement
US5594586A (en) * 1994-05-02 1997-01-14 The United States Of America As Represented By The Secretary Of The Air Force Photorefractive limiting quadratic processor
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6291675B1 (en) † 1996-05-21 2001-09-18 The United States As Represented By The Department Of Health And Human Services Methods of o-demethylation and n-deprotection
JP2001517689A (ja) † 1997-10-01 2001-10-09 フレミントン ファーマシューティカル コーポレイション 極性または非極性の、バッカルスプレーまたはカプセル
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
EP1905757A1 (en) 1999-04-06 2008-04-02 Sepracor Inc. Derivatives of Venlafaxine and methods of preparing and using the same
EP1180020B2 (en) † 1999-05-27 2009-06-24 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
US20020022662A1 (en) 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
DK1360169T3 (da) * 2001-02-12 2007-11-26 Wyeth Corp Succinatsalt af O-desmethyl-venlafaxin
UA80543C2 (en) * 2001-12-04 2007-10-10 Wyeth Corp Method for the preparation of o-desmethylvenlafaxine
RU2004139075A (ru) 2002-06-10 2005-06-27 Уайт (Us) Новые формиат 0-десметилвенлафаксина
TWI306092B (en) 2003-03-11 2009-02-11 Wyeth Corp Process for preparation of phenethylamine derivatives
KR20060132891A (ko) 2004-02-06 2006-12-22 와이어쓰 다중미립자 ｏ－데스메틸벤라팍신 염 및 그의 용도

Also Published As

Publication number Publication date
PA8539901A1 (es) 2005-05-10
WO2002064543A3 (en) 2002-12-12
NO20033538D0 (no) 2003-08-11
DK1360169T3 (da) 2007-11-26
HUP0303128A3 (en) 2008-03-28
EA200300873A1 (ru) 2003-12-25
US20030045583A1 (en) 2003-03-06
ES2290281T3 (es) 2008-02-16
ES2290281T5 (es) 2017-09-11
IL157340A (en) 2010-04-15
US7026508B2 (en) 2006-04-11
IL209444A0 (en) 2011-07-31
ATE369330T1 (de) 2007-08-15
NZ539791A (en) 2006-11-30
CA2666611A1 (en) 2002-08-22
CA2436668C (en) 2009-05-26
HK1057885A1 (en) 2004-04-23
SI1360169T1 (sl) 2007-12-31
IL200255A (en) 2010-12-30
AR082076A2 (es) 2012-11-07
EP2319826A1 (en) 2011-05-11
DE60221642T3 (de) 2017-10-26
JP2004529877A (ja) 2004-09-30
US20070037884A1 (en) 2007-02-15
US20050096479A1 (en) 2005-05-05
DE60221642D1 (en) 2007-09-20
CY1106952T1 (el) 2012-09-26
EA011451B1 (ru) 2009-04-28
US20040044241A1 (en) 2004-03-04
WO2002064543A2 (en) 2002-08-22
TWI318201B (en) 2009-12-11
PL396568A1 (pl) 2012-02-13
IL157340A0 (en) 2004-02-19
US6673838B2 (en) 2004-01-06
MXPA03007043A (es) 2003-11-18
US20090018208A1 (en) 2009-01-15
BR0207157A (pt) 2004-02-17
CN100567253C (zh) 2009-12-09
HUP0303128A2 (hu) 2003-12-29
CA2436668A1 (en) 2002-08-22
EP1360169B2 (en) 2017-05-24
EP1360169A2 (en) 2003-11-12
JP4220243B2 (ja) 2009-02-04
EP1864967A1 (en) 2007-12-12
CN101671260A (zh) 2010-03-17
PL364605A1 (en) 2004-12-13
EP1360169B1 (en) 2007-08-08
PL211788B1 (pl) 2012-06-29
KR20030077614A (ko) 2003-10-01
US7291347B2 (en) 2007-11-06
DE60221642T2 (de) 2008-05-21
NO20033538L (no) 2003-08-11
HN2002000030A (es) 2004-06-07
CN1501909A (zh) 2004-06-02
AR032671A1 (es) 2003-11-19
PT1360169E (pt) 2007-10-29
PE20020877A1 (es) 2002-11-12
IL209444A (en) 2012-10-31
PL212943B1 (pl) 2012-12-31
AU2002250058B2 (en) 2007-08-16
NO328807B1 (no) 2010-05-18
ZA200307116B (en) 2005-02-23
KR100875610B1 (ko) 2008-12-26

Similar Documents

Publication Publication Date Title
UY27175A1 (es) Nueva sal succinato de o-desmetil- venlafaxina
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
DE60201988D1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
EA200200571A1 (ru) Новая композиция и ее применение
DE60333294D1 (de) Kontrollierte verabreichung von arzneien
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
EA200300081A1 (ru) Гидрогель-управляемая лекарственная форма
SE0100901D0 (sv) New composition
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
ATE320256T1 (de) Succinate des 5,8,14-triazatetracyclo(10.3.1.0 2, 11 .0 4,9 )-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ATE401875T1 (de) Pharmazeutische feste dispersionen von modafinil- verbindungen
SE0101932D0 (sv) Pharmaceutical combinations
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
MA26899A1 (fr) PREPARATIONS CONTENANT UN MEDICAMENT GLUCOCORTICOiDE POUR LE TRAITEMENT DES MALADIES BRONCHOPULMONAIRES.
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
EP1663201A4 (en) USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
RS50523B (sr) Farmaceutska kompozicija koja sadrži cink-hijaluronat kompleks za lečenje multiple skleroze
SE0004827D0 (sv) Therapeutic compounds
ATE343390T1 (de) Kalzilytische verbindungen

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20171201